Abstract: FR-PO1113
Association Between Serum Chemerin Levels and Cardio-Ankle Vascular Index in Patients on Peritoneal Dialysis
Session Information
- Home Dialysis: Modalities, Barriers, Utilization, and Clinical Outcomes
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 802 Dialysis: Home Dialysis and Peritoneal Dialysis
Authors
- Chern, Yahn-Bor, Division of Nephrology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, Taiwan
- Tsai, Jen Pi, Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Dalin, Taiwan
- Chang, Ho-Hsiang, Division of Nephrology, Hualien Tzu Chi General Hospital, Hualien, Taiwan
- Hsu, Bang-Gee, Division of Nephrology, Hualien Tzu Chi General Hospital, Hualien, Taiwan
Background
Peripheral arterial stiffness (PAS) is a common vascular complication in patients undergoing peritoneal dialysis (PD) and is closely associated with adverse cardiovascular outcomes. Chemerin, an adipokine involved in inflammation, metabolic dysfunction, and vascular remodeling, has been implicated in cardiovascular disease. However, the relationship between circulating chemerin levels and PAS in PD patients remains unclear. This study aimed to investigate whether serum chemerin levels are associated with PAS, assessed using the cardio-ankle vascular index (CAVI), in patients receiving PD.
Methods
This cross-sectional study included 92 patients undergoing PAS. The CAVI was measured using the VaSera VS-1000 system, and PAS was defined as a CAVI >9.0 on either side. Serum chemerin levels were quantified using a commercial enzyme-linked immunosorbent assay.
Results
Among the 92 PD patients, 38 patients had PAS. Compared with the control group, patients with PAS were older (P = 0.008) and had greater waist circumference (P < 0.001), higher serum triglyceride (P = 0.009), fasting glucose (P = 0.027), C-reactive protein (CRP, P < 0.001), and chemerin (P < 0.001) levels, as well as a higher prevalence of diabetes mellitus (P = 0.026). In a multivariable logistic regression analysis, higher chemerin levels were independently associated with PAS (odds ratio [OR]: 1.042; 95% confidence interval [CI]: 1.019–1.065; P < 0.001). This association remained consistent across LASSO, Ridge, and Elastic Net penalized logistic regression models (all P < 0.001). Chemerin demonstrated good discriminatory ability for PAS, with the receiver operating characteristic (ROC) analysis showing an area under the ROC (AUC) of 0.848 (95% CI: 0.763-0.933; P < 0.001). Serum chemerin levels were positively correlated with left- or right-sided CAVI (all P < 0.001), waist circumference (P = 0.022), and log-transformed CRP (P < 0.001).
Conclusion
Higher circulating chemerin levels were independently associated with PAS in patients undergoing PAS. Chemerin demonstrated strong discriminatory performance in identifying PAS and may serve as a potential biomarker of vascular dysfunction in this population.